EQL — EQL Pharma AB Share Price
0.000.00%
Last trade - 00:00- SEK2.30bn
- SEK2.44bn
- SEK264.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 34.5 | ||
| PEG Ratio (f) | 1.13 | ||
| EPS Growth (f) | 44.03% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 11.04 | ||
| Price to Tang. Book | 230.04 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.79 | ||
| EV to EBITDA | 46.19 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 21.2% | ||
| Return on Equity | 18.23% | ||
| Operating Margin | 15.59% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 72.03 | 179.14 | 409.75 | 259.91 | 264.17 | 366.3 | 485.35 | 39.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +282.97 | +204.32 | -3.52 | -25.4 | +103.53 | +44.03 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.
Directors
- Gustav Kihlstrom CHM (65)
- Christer Fahraeus PRE (56)
- Axel Schorling DCE
- Anna Joensson CFO
- Alexander Brising VBD
- Charlotte Enochsson OTH
- Marianne Helgertz OTH
- Anna Rytter OTH
- Lars Holmqvist DRC
- Anders Mansson DRC
- Rajiv Modi DRC (60)
- Maria Ohlander DRC (47)
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 19th, 2006
- Public Since
- December 17th, 2013
- No. of Shareholders
- 961
- No. of Employees
- 28
- Sector
- Food & Drug Retailing
- Industry
- Consumer Defensives
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 29,063,610
- Address
- Stortorget 1, LUND, 222 23
- Web
- https://eqlpharma.com/
- Phone
- +46 462119170
- Auditors
- Deloitte AB
Upcoming Events for EQL
Similar to EQL
Apotea Sverige AB
OMX Nordic Exchange Stockholm
Axfood AB
OMX Nordic Exchange Stockholm
Herno Gin AB
OMX Nordic Exchange Stockholm
Newbury Pharmaceuticals AB
OMX Nordic Exchange Stockholm
Viva Wine AB
OMX Nordic Exchange Stockholm
FAQ
What is the EQL Pharma AB share price?
As of Today at 20:29 UTC, shares in EQL Pharma AB are trading at SEK79.00. This share price information is delayed by 15 minutes.
How has the EQL Pharma AB share price performed this year?
Shares in EQL Pharma AB last closed at SEK79.00 and the price had moved by +83.72% over the past 365 days. In terms of relative price strength the EQL Pharma AB share price has outperformed the FTSE Global All Cap Index by +79.12% over the past year.
What are the analyst and broker recommendations for EQL Pharma AB?
There is no consensus recommendation for this security.
Find out moreWhat is the EQL Pharma AB dividend yield?
EQL Pharma AB does not currently pay a dividend.
Does EQL Pharma AB pay a dividend?
EQL Pharma AB does not currently pay a dividend.
When does EQL Pharma AB next pay dividends?
EQL Pharma AB does not currently pay a dividend.
How do I buy EQL Pharma AB shares?
To buy shares in EQL Pharma AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of EQL Pharma AB?
As of the previous close price of SEK79.00, shares in EQL Pharma AB had a market capitalisation of SEK2.30bn.
Where are EQL Pharma AB shares listed?
Here are the trading details for EQL Pharma AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: EQL
What kind of share is EQL Pharma AB?
Based on an overall assessment of its quality, value and momentum EQL Pharma AB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a EQL Pharma AB share price forecast for 2025?
The analyst consensus target price for shares in EQL Pharma AB is SEK77.00. That is 2.53% below the last closing price of SEK79.00.
Analysts covering EQL Pharma AB currently have a consensus Earnings Per Share (EPS) forecast of SEK1.59 for the next financial year.
Find out moreWhat is the trend in the EQL Pharma AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like EQL Pharma AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +23.66%.
As of the last closing price of SEK79.00, shares in EQL Pharma AB were trading +15.76% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the EQL Pharma AB PE Ratio?
The EQL Pharma AB PE ratio based on its reported earnings over the past 12 months is 34.5. The shares last closed at SEK79.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of EQL Pharma AB?
EQL Pharma AB's management team is headed by:
- Gustav Kihlstrom - CHM
- Christer Fahraeus - PRE
- Axel Schorling - DCE
- Anna Joensson - CFO
- Alexander Brising - VBD
- Charlotte Enochsson - OTH
- Marianne Helgertz - OTH
- Anna Rytter - OTH
- Lars Holmqvist - DRC
- Anders Mansson - DRC
- Rajiv Modi - DRC
- Maria Ohlander - DRC